文献速递神经核医学

双同位素CZT SPECT/CT同步灌注与多巴胺能成像在路易体痴呆中的应用

Simultaneous perfusion and dopaminergic imaging using dual-isotope CZT SPECT/CT in dementia with Lewy bodies.
PubMed 文献 · EJNMMI Res · 2026-02-07

本研究回顾性纳入56例临床诊断为路易体痴呆(DLB)的患者,采用CZT SPECT/CT进行双同位素同步脑灌注与多巴胺转运体成像。结果显示84%患者多巴胺转运体摄取减低,100%患者存在脑灌注减低,且多巴胺转运体正常者均伴有灌注异常,提示该技术可单次评估多个生物标志物。

要点

  • 双同位素CZT SPECT/CT可单次同步评估DLB的指示性及支持性生物标志物。
  • DLB患者中多巴胺转运体摄取减低者占84%,脑灌注减低者占100%。
  • 多巴胺转运体正常者均存在灌注异常,部分伴支持性标志物。

核心结论

  • 双同位素脑SPECT在DLB患者中常发现多巴胺转运体异常,且总与灌注异常并存。
  • 多巴胺转运体正常者均存在灌注异常,该技术可更全面评估DLB生物标志物而不增加扫描时间。

研究设计与样本

  • 回顾性单中心研究,纳入56例连续临床诊断为DLB并接受双同位素脑SPECT的患者,平均年龄80.4±7.8岁,女性占34%。

主要发现

  • 多巴胺转运体摄取减低(指示性生物标志物)见于84%的患者,脑灌注减低见于100%的患者。
  • 支持性生物标志物扣带回岛征和枕叶灌注减低分别见于29%和55%的患者。
  • 9例多巴胺转运体正常者均存在脑灌注减低,其中3例呈现DLB支持性生物标志物。
  • 影像生物标志物结果与整体认知评分、各核心临床特征、内侧颞叶萎缩或AD脑脊液生物标志物之间无显著关联。

临床怎么用

  • 对于临床疑诊DLB的挑战性病例,可采用双同位素CZT SPECT/CT单次扫描同步评估多巴胺转运体与脑灌注,提高诊断信心。

局限性

  • 回顾性单中心设计,样本量有限(56例),仅纳入临床诊断为DLB的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current diagnostic criteria for dementia with Lewy bodies (DLB) include indicative and supportive biomarkers, some of which are typically assessed separately using dopamine transporter or perfusion imaging. Cadmium-zinc-telluride (CZT) Single Photon Emission Computed Tomography (SPECT) cameras improve simultaneous dual isotope acquisition using [99mTc]-hexamethylpropyleneamine oxime ([99mTc]TcHMPAO) (perfusion) and N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl)nortropane ([123I]FP-CIT; dopamine transporter), allowing the assessment of one indicative and two supportive biomarkers in a single session. This study aimed to describe the results of dual-isotope brain SPECT imaging in a cohort of patients clinically diagnosed with DLB and to compare clinical characteristics, cognition, structural atrophy, and Alzheimer’s disease (AD) biomarkers, between imaging outcomes. RESULTS: This retrospective single-center study included a total of 56 consecutive patients (mean ± standard deviation age 80.4 ± 7.8 years; 34% females) referred from an expert memory center finally diagnosed as DLB and who underwent a dual-isotope brain SPECT. Based on core clinical features from Mc Keith et al. revised diagnostic criteria, 40 patients (71%) were classified as probable DLB and 16 (29%) as possible DLB. Reduced dopamine transporter uptake (indicative biomarker) was observed in 84% of patients, while cerebral hypoperfusion was found in 100%. Supportive biomarkers such as cingulate island sign and occipital hypoperfusion were present in 29% and 55%, respectively. All 9 patients with normal dopamine transporter imaging had cerebral hypoperfusion and 3 of them presented supportive biomarkers of DLB. No significant association was found between imaging biomarker results and global cognition score, each core clinical features individually, medial temporal lobe atrophy, or CSF biomarkers for AD. CONCLUSION: Dual-isotope brain SPECT using CZT frequently identifies dopamine transporter abnormalities in patients with DLB, always in conjunction with perfusion abnormalities. Patients with normal dopamine transporter imaging always present perfusion abnormalities. This imaging approach provides a more comprehensive assessment of indicative and supportive biomarkers in DLB, without increasing scan duration, potentially enhancing diagnostic confidence in clinical practice, particularly in challenging cases.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gayor C, Scheiber C, Janier M, et al. Simultaneous perfusion and dopaminergic imaging using dual-isotope CZT SPECT/CT in dementia with Lewy bodies. EJNMMI Res. 2026. PMID: 41653279. doi:10.1186/s13550-026-01386-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。